You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Chemotherapy and other systemic treatment regimens may change due to COVID-19. Find out more at Systemic Treatment Regimens During COVID-19.

Funded Evidence-Informed Regimens

Drug and regimen monographs and information sheets for patients provide information on dosing and administering cancer treatment protocols. They are for general reference and are not meant to replace prescribing information or physician recommendations.

If you have questions about ST-QBP funding on our website, please visit our Frequently Asked Questions page.

Find enhanced Regimen Patient Information Sheets, created in collaboration with patient and family advisors.

Regimens

9 Items
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
Nov 2020
Cancer Type: Hematologic, Lymphoma - Non-Hodgkin's High Grade, Lymphoma - Non-Hodgkin's Intermediate Grade, Lymphoma - T-cell     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
ODB - General Benefit
    etoposide - oral capsules
Feb 2021
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
May 2018
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative, Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - In Combination with Chemotherapy for Previously Untreated Peripheral T-cell Lymphoma (PTCL)
ODB - General Benefit
    prednisone
Nov 2020
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative, Palliative
May 2019
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative
Funding:
ODB - General Benefit
    dexamethasone
May 2019
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Dec 2020
Cancer Type: Hematologic, Leukemia - Acute Lymphoblastic (ALL), Lymphoma - T-cell     
Intent: Curative
Drugs Used:
pegaspargase (Unfunded)
Feb 2021
Cancer Type: Hematologic, Lymphoma - T-cell     
Intent: Curative
May 2019